Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-0120 in Primary Hyperuricemia Phase II Trial
CTR20221594Phase 2Completed
- Sponsor
- EpimAb Biotherapeutics
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of darbinurad in Primary Hyperuricemia, gout, sponsored by EpimAb Biotherapeutics. Started Jun 2022; status: completed.
02
Drugs
darbinurad
03
Conditions
Primary Hyperuricemiagout
Beyond the preview
Go deeper on CTR20221594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221594.